Results 141 to 150 of about 12,578,048 (280)

During pregnancy, anticoagulant effect of low molecular weight heparin can be determined with both thrombelastography and anti-factor Xa activity, or not? [PDF]

Anaesth Intensive Care
Carlberg N, Olsson A, Hellgren M, Karlsson O.   +3 more
europepmc   +1 more source

Small scale purification and biophysical characterization of haptoglobin derived from human Cohn fraction IV

Biotechnology Progress, EarlyView.
Abstract Haptoglobin (Hp) is a polymorphic acute phase α‐2 glycoprotein found in plasma that plays a critical role in binding, neutralizing, and removing cell‐free hemoglobin (Hb) from the circulation. Under clinical conditions characterized by high levels of hemolysis, such as in patients with sickle cell disease (SCD), large quantities of cell‐free ...
Shuwei Lu, Mohd Asim Khan, Pedro Cabrales, David C. Irwin, Paul W. Buehler, Andre F. Palmer   +5 more
wiley   +1 more source

Assessment of Anti-Factor Xa Levels in Children Receiving Low-Molecular-Weight Heparin for Treatment and Prophylaxis. [PDF]

Children (Basel)
Panova M, Spasova M, Stoencheva S, Dimcheva T, Sotkova-Ivanova I, Boykova P.   +5 more
europepmc   +1 more source

Fibrilpaint: A Class of Amyloid‐Targeting Peptides

Chemistry – A European Journal, EarlyView.
FibrilPaints are modular peptides engineered to recognize amyloid fibrils. By systematically varying charge, sequence, and termini, their binding behavior can be tuned while retaining recognition. Successful binding ″paints″ fibrils for visualization and opens routes toward targeted degradation and diagnostic applications.
Júlia Aragonès Pedrola, Françoise A. Dekker, Katrin Guttmann, Litske M. van Leeuwen, Shalini Singh, Guy Mayer, Tommaso Garfagnini, Assaf Friedler, Stefan G. D. Rüdiger   +8 more
wiley   +1 more source

Low-molecular-weight heparin in patients with renal insufficiency

Swiss Medical Weekly, 2009
AG Fischer
doaj   +1 more source

Meta-analysis of Randomized Trials in Emergency and Acute Orthopedic Trauma Comparing Aspirin and Low-Molecular-Weight Heparin for Thromboprophylaxis. [PDF]

Orthop Rev (Pavia)
Alshehri AF, Samarkandi WO, Muhanad L, Mesri HE, Bin Salleeh OH, AlAmiri AM, Bukhari AA, Alshehri AM, Alrajeh AA, Alrazoq FA, Alshawaf AA, Alzamel AA, Alsheikh Tahboub MM, Albadawi MI, Alqahtani SS.   +14 more
europepmc   +1 more source

Intravenous Lipopolysaccharide Challenge in Healthy Participants Reveals Pharmacodynamic Markers in Blood and Bone Marrow for Early‐Phase Oncology Drug Development

Clinical Pharmacology &Therapeutics, EarlyView.
Demonstrating pharmacological effects in early‐phase oncology clinical trials remains challenging, largely due to the lack of robust pharmacodynamic markers. Lipopolysaccharide (LPS) is used as an immune challenge agent in healthy participants to study drugs for autoimmune conditions.
Igor Radanović, Ingrid Tomljanović, Wieke H. Grievink, Diana R. Pereira, Michelle Osse, Peter van Balen, Maria J. Juachon, Marieke L. de Kam, Lisa Pagan, Manon A.A. Jansen, Matthijs Moerland, Jacobus J. Bosch   +11 more
wiley   +1 more source

Apixaban Versus Low-Molecular-Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis. [PDF]

J Clin Med
Aggarwal S, Singh V, Bhasin A, Anand S, Tabassum H.   +4 more
europepmc   +1 more source

The effect of heparin and low molecular weight heparin fractions on platelet aggregation

, 1990
Kollagen ve ADP ile oluşturulan trombosit agregasyonu üzerine heparin (liquemin) ve CY 216 ile CY 222 kodlu düşük moleküler ağırlıklı heparin fraksiyonlarının etkileri araştırıldı.
Ulutin, Orhan N.
core  

From Biological Mechanisms to Causal Inference: Quantitative Systems Pharmacology and Causal Frameworks in Drug Development

Clinical Pharmacology &Therapeutics, EarlyView.
Digital patients and in silico clinical trials offer new opportunities to advance pharmacological research, clinical development, and regulatory decision‐making by enabling the simulation of treatment effects prior to testing in patients. Among the most promising of these opportunities is the combined use of quantitative systems pharmacology (QSP) and ...
Thomas Klabunde, Ramon Hernandez, Piet H. van der Graaf, Tommaso Andreani   +3 more
wiley   +1 more source